Collagen Diseases  >>  Artlegia (olokizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Artlegia (olokizumab) / R-Pharm
NCT01463059: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed
2
119
Japan, RoW
Placebo, Olokizumab 60 mg, CDP6038, Olokizumab 120 mg, Olokizumab 240 mg
UCB Japan Co. Ltd.
Rheumatoid Arthritis
02/13
02/13

Download Options